May 2, 2008 - Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. This official notification sets forth the remaining conditions that must be satisfied to gain U.S. marketing approval for Surfaxin... [PDF] Discovery Labs' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
May
(42)
- Delphi Medical Systems : New Delphi Portable Oxyge...
- ImClone : Significant Data on ERBITUX (cetuximab)...
- Olympus Medical Systems and Spiration : Agreement ...
- Pfizer : New Data in Lung Cancer to Be Presented a...
- Array BioPharma and AstraZeneca : New Phase 2 Dev...
- Guided Therapeutics, Inc. and Konica Minolta : to ...
- Arriva Pharmaceuticals Granted Fusion Protein Patent
- EPIX Pharmaceuticals : Phase 2a Data at American T...
- Osiris Therapeutics : Phase II Clinical Trial Eval...
- 3M : First FDA-Cleared Respirators for General Pub...
- VGX Pharmaceuticals : multi-year production agreem...
- Nektar : Patent Covering Pulmonary Targeted Antibi...
- Oscient & Menarini : Regulatory Filing for FACTIVE...
- GE HEALTHCARE & Merck : GLOBAL MOLECULAR DIAGNOSTI...
- Sepracor & Arrow : Global License and Development ...
- Critical Therapeutics : Definitive Agreement to Me...
- KaloBios : Patient Dosing in its U.S. Phase 1 Tria...
- Compugen : Discovery of Blood Based Biomarker for ...
- Nabi Biopharmaceuticals Prevails in Opposition Hea...
- Gilead : Letairis (ambrisentan) Phase IV Program
- Targacept : Designation of Lead Compound in Smokin...
- GenVec : Grant for RSV Vaccine Program
- Pipex Pharmaceuticals : FDA Orphan Drug Designatio...
- Pfizer Japan : Champix the First Prescription Ora...
- Masimo : new Rad-87 Pulse CO-Oximeter, Patient Saf...
- Discovery Labs : Approvable Letter from FDA for Su...
- PARI : eFlow delivers Alnylam RNAi Therapeutic in ...
- Monogram Biosciences : HER1 and HER3 VeraTag™ Assa...
- MedImmune : Phase 3 Data Regarding Anti-RSV Antibo...
- United Therapeutics : Treprostinil Data Presented...
- Oncothyreon's PX-12 and PX-866 Data presented at A...
- GlaxoSmithKline : further progress of oncology por...
- AstraZeneca : Marketing Application in Europe for ...
- Proteolix : Phase 2 Clinical Trial of Carfilzomib ...
- Poniard Pharmaceuticals : Final Picoplatin Data fr...
- Boehringer Ingelheim : Data suggests promising ove...
- Biomoda : Allowance allows company to expand paten...
- Roche acquires Piramed
- Biocon Limited : Phase IIb trials for NSCLC for B...
- Nonin Medical : World’s first Bluetooth-enabled, w...
- AstraZeneca : an sNDA for SYMBICORT for COPD indic...
- GlaxoSmithKline : Advair 250/50 for reduction of e...
-
▼
May
(42)
May 8, 2008
Discovery Labs : Approvable Letter from FDA for Surfaxin for RDS
May 2, 2008 - Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that it has received an Approvable Letter from the U.S. Food and Drug Administration (FDA) for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. This official notification sets forth the remaining conditions that must be satisfied to gain U.S. marketing approval for Surfaxin... [PDF] Discovery Labs' Press Release -
